Agentix Corp. (AGTX) stock
Close on Oct 16, 2026Market cap $801.34KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $801.34K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$417.49K
- EPS, diluted
- $0.00
- Book value per share
- -$0.09
- Diluted shares
- 40M
Trading
- Previous close
- $0.02
- Open
- $0.02
- Day's range
- $0.02 – $0.02
- Volume
- 0
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | AGTX | S&P 500 | Difference | AGTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +1.5% | −1.5 pts | ||
| 3 months | 0.0% | +1.9% | −1.9 pts | ||
| Year to date | -46.7% | +12.8% | −59.5 pts | ||
| 1 year | -59.9% | +16.8% | −76.7 pts | ||
| 3 years | -71.8% | +81.5% | −153.3 pts | -34.4% | +22.0% |
| 5 years | -97.5% | +83.0% | −180.5 pts | -52.2% | +12.8% |
| 10 years | -99.9% | +319.4% | −419.3 pts | -51.0% | +15.4% |
Twelve years at a glance
Fiscal years 2013 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Agentix filed with the SEC as exhibits to Form 8-K or 6-K
About Agentix
Biological Products, (No Diagnostic Substances)
Agentix Corp. is a clinical-stage biopharmaceutical company that focuses on developing treatments for metabolic disorders, including type 2 diabetes, obesity, and fatty liver disease. The company's therapeutic pipeline centers on peripherally-restricted cannabinoid type 1 receptor antagonists and inverse agonists designed not to cross the blood-brain barrier. Its primary product candidates include AGTX-2004, a CB1 receptor antagonist advancing toward human clinical trials, and AGTX-2003, an inverse agonist undergoing preclinical evaluation. Because its drug candidates remain in development without commercial sales, the firm has no commercial customers, though it aims to partner with larger pharmaceutical corporations.
Company profile, executives and historyAgentix stock: common questions
What is Agentix's stock price?
AGTX closed at $0.02 on Oct 16, 2026, up 0.00% on the day.
What is Agentix's market cap?
Agentix was worth $801.34K at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is AGTX's P/E ratio?
Agentix lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
Does Agentix pay a dividend?
No. Agentix has not paid a cash dividend over the last twelve months.
How has AGTX stock performed over the past year?
Including dividends, AGTX returned -59.9% over the past year, against +16.8% for the S&P 500.
Who are Agentix's competitors?
Companies most similar to Agentix by business, industry and size include OKYO, KLRS, ELOX, NMRA, MAZE.
See a number that looks wrong?